A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Single and Multiple Ascending Dose Study of AS902330 (rhFGF-18) Administered Intra-Articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement.
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2016
At a glance
- Drugs Sprifermin (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; Biomarker; First in man
- Sponsors Merck KGaA
- 10 Jun 2017 Biomarkers information updated
- 23 Mar 2016 Results published in the Clinical and Experimental Rheumatology
- 14 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.